A BIO4 Campus representative joined a Serbian delegation on a study visit to Denmark from June 1–3, aimed at exploring the institutions, partnerships, and governance models that have helped establish one of Europe's most advanced life science ecosystems.

The program included meetings with the Danish Life Science Cluster, BioInnovation Institute (BII), the Danish Medicines Agency (DKMA), Trial Nation, Healthcare Denmark, and Bioneer, as well as discussions with representatives of the Embassy of the Republic of Serbia in Denmark.

A coordinated ecosystem, not individual institutions

Throughout the visit, a common theme emerged: Denmark's success is not based on individual institutions alone, but on a highly coordinated ecosystem that connects research, healthcare, industry, regulators, investors, and public authorities around shared strategic goals.

Key topics discussed included:

• Ecosystem governance and public-private collaboration — mechanisms that enable sustainable cooperation between academia, healthcare providers, companies, investors, and government institutions
• Research commercialization and startup development — support structures that help scientific discoveries progress from laboratories to scalable companies, including funding, mentoring, translational infrastructure, and investor engagement
• Clinical research excellence — Denmark's coordinated approach to clinical trials, including early-phase studies, regulatory support, accelerated assessment pathways, and national trial coordination mechanisms
• Advanced therapies and translational medicine — development of ATMP ecosystems, GMP infrastructure, manufacturing readiness, and strategies for translating scientific discoveries into clinical and commercial applications
• Digital health, health data, and artificial intelligence — governance frameworks, interoperability, responsible use of health data, and the role of digital infrastructure in enabling innovation
• Living Labs and healthcare implementation — how innovations are tested, validated, and scaled within real healthcare environments through collaboration between public and private stakeholders
• Internationalization and ecosystem development — opportunities for cross-border partnerships, participation in European projects, talent attraction, and collaboration between mature and emerging innovation ecosystems

Applying Danish lessons to BIO4's development

Particularly valuable were discussions on how Denmark aligns incentives across institutions, integrates regulators into innovation processes, supports scientific founders, coordinates clinical research nationally, and builds translational infrastructure that bridges academic excellence with societal and economic impact.

Many of these experiences are directly relevant for the continued development of BIO4 Campus and Serbia's ambition to become a regional hub for biotechnology, biomedicine, bioinformatics, and biodiversity. The visit opened new opportunities for future partnerships between Denmark and Serbia, and provided important perspectives for strengthening innovation, translational medicine, clinical research, and international collaboration.